Lightcalls.com
 

Previous fears that soy-rich diets ...

Previous fears that soy-rich diets contribute to breast cancer have been eased. In fact, according to the novel research, soy could actually cut down a woman's odds of developing the disease.

It was formerly believed that consumption of tofu, soybeans and soy milk lowered the incidence of compact breast tissue, which is considered a high risk for breast cancer.

Then a scientists hinted that the estrogenic mingles in soy might interfere with hormone on a levels and encourage the growth of breast tumors. While the debate lacked scientific evidence, many women backed away from soy

However, according to recent research from three institutions--Cancer Research UK based in London; the National University of Singapore; and the National Cancer Institute in Bethesda, Maryland--soy could help bring to a woman's odds of developing breast cancer.

The scientists analyzed the proceeds from two previous studies carried public in Singapore: one that researched women's diets and another that analyzed breast tissue density.



In the researchers' of recent origins release, women who ate the mostly soy were 60 percent les likely to have the high-risk breast tissue than women who consum the least soy

The researchers believe that the benefit could approach from a compound in soy called isoflavone, which mimics the action of the female hormone estrogen

Although like phytoestrogens (plant-based estrogens) are not as robust as the estrogen that the corpse produces, they appear to lengthen a woman's menstrual period Previous studies show that the fewer menstrual periods a woman has in her lifetime, the lower her risk of breast cancer.

"These findings make an important contribution toward our ongoing studies forward the relationship between diet and cancer, and they may eventually point to recent ways of preventing breast cancer," says Sir Paul suckle Interim Chief Executive of Cancer Research UK

The novel study supports the results of an April 2000 reflection at the University of Toronto's department of Nutritional Sciences, where, researchers fix that soy poses no higher risk of breast cancer.

David Jenkins, PhD who l the Toronto thought says, "The concern had been whether soy estrogen might actually lead to hormone-dependent breast cancer, still our researchers found no evidence of this."

COPYRIGHT 2002 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved

COPYRIGHT 2002 Gale Group



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.